Xovoltib 40mg (Afatinib Dimaleate)

Product Overview

Xovoltib 40mg contains Afatinib Dimaleate, a potent tyrosine kinase inhibitor (TKI) specifically designed to treat metastatic or advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Afatinib is a permanent blocker of this ErbB group of receptors, which are the primary drivers for the proliferation of tumor cells and their longevity.

In its second generation, EGFR TKI Xovoltib provides significant medical advantages for those suffering from NSCLC with an improved prognosis and treatment control, especially when patients are resistant to the first generation of EGFR inhibitors.

Composition

• Active Ingredient: Afatinib Dimaleate – 40 mg per tablet
• Excipients: Microcrystalline cellulose, lactose monohydrate, magnesium stearate, and other inactive ingredients
• Form: Film-coated oral tablet
• Packaging: Blister packs of 7 tablets

Indications

Xovoltib 40mg is indicated for:

• The first-line treatment for metastatic and advanced NSCLC is by activating EGFR modifications (exon 19 deletions or exon 21 L858R substitution mutations).
• Treatment for patients suffering from EGFR T790M mutations who are positive for NSCLC that are not responding to previous EGFR TKIs (in certain clinical situations).
• Patients suffering from Squamous NSCLC who have advanced on platinum-based therapy (depending on the approval of regulatory authorities).

Mechanism of Action

Afatinib is an irreversible inhibitor of the ErbB receptor family, which includes:

• EGFR (ErbB1)
• HER2 (ErbB2)
• HER4 (ErbB4)

In covalently binding with the receptors mentioned above, afatinib:

• Blocks the phosphorylation process and activates downstream signaling pathways, such as RAS/RAF/MEK/ERK and PI3K/AKT.
• The inhibitor blocks the growth of cancerous cells and triggers Apoptosis.
• It overcomes resistance mechanisms for the first-generation EGFR TKIs via irreversible binding.

Benefits of Xovoltib

• Targeted therapy: It targets tumor cells in a selective manner with particular EGFR mutations.
• Improves progression-free survival: This slows down the growth of tumors as well as the progression of the disease.
• Oral administration: Dosing is simple and easy at home.
• Overcomes resistance: Some patients are not responding to previous EGFR inhibitors.
• Well-studied: Clinical trials have proven efficiency and safety.
• Better quality of life: As compared to chemotherapy, the drug has a much better adverse effect profile.

Dosage and Administration

• Recommended Dose: 40 mg once a day orally and with or without food.
• Dose Adjustments: In accordance with tolerance levels, dose adjustments to 20 or 30 mg daily could be required.
• Treatment Duration: Do not stop until there is a progression of disease or unacceptably toxic.
• Missed Dose: Do it as quickly as you remember or until the next dose. Do not take more than one dose.

Important: Does it at the same time every day, to ensure the same levels of the drug.

Side Effects

Common adverse reactions include:

• Diarrhea (most frequent; may require dose adjustment)
• Skin rash and acne
• Mouth sores (stomatitis)
• Dry skin and itching
• Nail inflammation and infections
• Fatigue and weakness
• Decreased appetite
• Nausea and vomiting

Serious side effects may include:

• Interstitial lung disease (shortness of breath, cough)
• Liver toxicity (jaundice, dark urine)
• Severe diarrhea leading to dehydration
• Eye inflammation (conjunctivitis, keratitis)

Patients are advised to be aware of any persistent or severe signs immediately.

Precautions and Warnings

• Baseline assessment: Do pulmonary function tests and test for liver function prior to beginning treatment.
• Monitor for diarrhea: Be sure to take action quickly in order to avoid dehydration.
• Liver toxicity: Monitor liver enzymes regularly.
• Avoid pregnancy: Afatinib is teratogenic, and an effective contraception method is needed in the course of treatment as well as throughout the months following treatment.
• Drug interactions: Beware of concomitant use with stronger CYP3A4 stimulants or inhibitors in the absence of medical advice.
• Dose modification: Required for reactions that cause adverse reactions in order to increase tolerance.
• Renal and hepatic impairment: Be cautious and alter the dosage according to your needs.
• Not for pediatric use: Insufficient evidence of safety and efficacy among children.

Storage

• The tablets should be stored in the original packaging between 20°C and 25°C (room temperature).
• Guard against light and moisture.
• Be sure to keep away from young children.

Frequently Asked Questions (FAQs)

How quickly does Xovoltib work?

The clinical benefits, which include the shrinkage of tumors and relief of symptoms, generally show results within a few weeks; it is essential to continue treatment.

Can I take Xovoltib with food?

Yes, Xovoltib may indeed be used in combination with and without meals.

What should I do if I miss a dose?

Make sure to take the dose missed as fast as you can, unless it’s close to the scheduled dose. Avoid double doses.

Is Xovoltib a cure for lung cancer?

Xovoltib isn’t an effective cure, but it can help slow the progression of the disease and increase longevity.

Can I drive or operate machinery?

Certain patients might feel dizzy or fatigued. Do not engage in such activities if you are feeling tired or weak.

Why Choose Xovoltib 40mg?

• A highly specific and efficient treatment for EGFR mutation-related NSCLC.
• The ease of oral therapy can improve patients’ acceptance.
• It has been proven clinically that it can slow down the progression of the disease and increase the quality of living.
• The research is backed by rigorous clinical studies as well as regulatory approvals.

Conclusion

Xovoltib 40mg (Afatinib Dimaleate) is a powerful and targeted oral treatment for patients with advanced, non-small cell cancer of the lung that has particular EGFR mutations. Through irreversibly blocking this ErbB receptor family of proteins, it stops the growth of cancer and slows its progression of cancer with moderate safety and efficacy.

In order to achieve optimal results, treatment with Xovoltib is recommended to be governed by molecular testing with careful surveillance, as well as constant communication with your oncology treatment team.